Table 1.
Demographics and immunomodulatory drug use among patients with RA and OA as well as normal subjects.
| RA Active | RA Controlled | OA | Normal | |
|---|---|---|---|---|
| Number of Subjects | 20 | 7 | 21 | 3 |
| Age Range (years) | 33–75 | 49–78 | 39–88 | 44–68 |
| Mean Age | 55 | 63 | 63 | 57 |
| Gender (F vs. M) | 15(75%)/5(25%) | 7(100%)/0(0%) | 11(52%)/10(48%) | 2(66%)/1(33%) |
| BMI | ||||
| Range | 20–35 | 17–37 | 23–41 | 21–24 |
| Mean | 26 | 27 | 30 | 22 |
| Number on Prednisone, DMARD or Biologic | 11 (58%) | 6 (86%) | 1 (5%) | 0 |
| Prednisone | 6 (32%) | 1 (14%) | 0 | 0 |
| Infliximab | 3 (16%) | 0 | 0 | 0 |
| MTX | 2 (11%) | 2 (29%) | 0 | 0 |
| HCQ | 3 (16%) | 3 (43%) | 1 | 0 |
| Rituximab | 2 (11%) | 1 (14%) | 0 | 0 |
| Tocilizumab | 1 (5%) | 1 (14%) | 0 | 0 |
| Sulfasalazine | 1 (5%) | 0 | 0 | 0 |
| Etanercept | 1 (5%) | 0 | 0 | 0 |
| Adalimumab | 1 (5%) | 0 | 0 | 0 |
| Golimumab | 0 | 1 (14%) | 0 | 0 |
| +RF > 14 | 7 (35%) | 6 (86%) | ND | ND |
| +CCP > 20 | 10 (50%) | 6 (86%) | ND | ND |
| SF WBC (cells/mm3) | ||||
| Range | 331–65,000 | 8–270 | 0–260 | 0 |
| Mean | 9620 | 85 | 131 | 0 |
Legend: RA = rheumatoid arthritis, OA = osteoarthritis, Normal = asymptomatic recreational runners without knee pain, RA active = patients with SF WBCs > 300 mm3, RA controlled = patients with SF WBCs < 300 cells/mm3, BMI = body mass index, MTX = methotrexate, HCQ = hydroxychloroquine, +RF = rheumatoid factor with an antibody titer > 14, and +anti-CCP = antibodies to cyclic citrullinated peptide antigens with a value of > 20 units.